Relmacabtagene Autoleucel Injection (CXSS2000036) Application for Technical Review Report for Market Authorization

Update: 29 October, 2023

Relmacabtagene Autoleucel Injection (CXSS2000036) is a biological product used to treat relapsed or refractory large B cell lymphoma in adult patients after two or more lines of systemic therapy.


File format: PDF

Size: -

MD5 Checksum: ABC323AB07A3F562A2DE1A8F66EB5CC0

Publication date: 29 October, 2023

Downloads: -

PDF Link: Relmacabtagene Autoleucel Injection (CXSS2000036) Application for Technical Review Report for Market Authorization PDF

Also Manuals